ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MED vs BYND // EV/EBITDA & P/E VALUATION

MEDIFAST INC (NYSE) VS. Beyond Meat Inc. (NASDAQ) • 15-METRIC TALLY: MED 6 — BYND 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. BYND) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MED BYND SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 71.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -10.20% -35.00% +24.80 MED /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.91% — — TIE /fcf-yield <GO>
Operating Margin -3.70% -60.00% +56.30 MED /operating-margins <GO>
Net Profit Margin -4.90% 68.00% -72.90 BYND /net-margins <GO>
Revenue Growth (YoY) -36.00% -15.60% -20.40 BYND /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.14% 0.00% +0.14 MED /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.71 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 MED /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.3 36.5 +17.74 MED /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $137.1M $126.9M $10.2M MED /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MED REV BYND REV MED GROSS % BYND GROSS % MED FCF BYND FCF
FY 2025 $385.8M $275.5M 71.3% 2.8% $1.2M -$157.2M
FY 2024 $602.5M $326.5M 73.8% 12.8% $17.0M -$109.8M
FY 2023 $1.07B $343.4M — — $147.7M -$107.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
BYND // BETA —